3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
35
Rectal Neoplasms
24
Stomach Neoplasms
19
Triple Negative Breast Neoplasms
16
Colorectal Neoplasms
14
Neoplasm Metastasis
12
Adenocarcinoma
9
Pancreatic Neoplasms
8
Esophageal Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Nasopharyngeal Carcinoma
7
Adenocarcinoma Of Esophagus
7
Neoplasms
6
Colonic Neoplasms
6
Biliary Tract Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Esophageal Squamous Cell Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Spinocerebellar Degenerations
2
Pathologic Complete Response
2
Ovarian Neoplasms
2
Neoplasm, Residual
2
Locally Advanced Rectal Cancer
2
Carcinoma
2
Anus Neoplasms
2
Advanced Solid Tumour
2
Somatostatinoma
1
Solid Tumors
1
Resectable Colon Cancer
1
Rectal Cancer Patients
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Capecitabine
×
90 days
×
Clear all
No trials found.